The FDA sent reminders to more than 2,200 sponsors and investigators tied to over 3,000 clinical trials that may be delinquent in disclosing results on ClinicalTrials.gov. The agency’s action follows an internal review indicating that results were not reported for about 30% of registered clinical studies. The regulator said the reminder is intended to improve completeness and timeliness of public disclosure as part of ongoing efforts to strengthen transparency around clinical evidence. Sponsors are expected to address missing results in line with reporting requirements tied to study completion milestones. The update matters operationally for biotech trial programs, because incomplete disclosure can affect investigator and sponsor compliance standing and can complicate scientific interpretation and competitive positioning in crowded disease areas.